What is Theravance Biopharma's operating lease liabilities?

Theravance Biopharma (TBPH) reported operating lease liabilities of -$2.2M in Q1 2026.

How has Theravance Biopharma's operating lease liabilities changed year-over-year?

Theravance Biopharma's operating lease liabilities decreased by 32.2% year-over-year, from -$1.66M to -$2.2M.

What is the long-term trend for Theravance Biopharma's operating lease liabilities?

Over 3 years (2021 to 2025), Theravance Biopharma's operating lease liabilities has grown at a 27.1% compound annual growth rate (CAGR), from -$3.47M to -$7.12M.

Theravance Biopharma TBPH Operating lease liabilities

Operating lease liabilities at other companies

Zevra Therapeutics, Inc.ZVRA

——

Aurinia PharmaceuticalsAUPH

——

PrecigenPGEN

——

Mirum Pharmaceuticals, Inc.MIRM

——

BridgeBio PharmaBBIO

——

Roivant SciencesROIV

——

Other financials

Income statement

See full

Revenue$17.7M+15.0%

Operating income-$9.5M+34.3%

Net income-$4.9M+63.7%

EPS (diluted)-$0.10+63.0%

Balance sheet

See full

Cash & equivalents$288.1M+160%

Total debt$40.5M-15.9%

Total equity$290.6M+75.1%

Total assets$472.3M+37.5%

Cash flow

See full

Operating cash flow$73.3M+70.3%

CapEx$8.0K-95.8%

Free cash flow$59.6M+5,560%

Valuation

See full

Market cap$896.51M+68.7%

Enterprise value$648.91M+38.3%

P/E7.8×—

P/S8.2×0.0×

Profitability

See full

Gross margin60.8%—

Operating margin1.2%+0.6pp

Net margin104.3%+71.4pp

FCF margin221.9%+206pp

Returns & leverage

See full

Return on equity50.2%+36.2pp

Debt / equity0.1×-0.2×

Current ratio13.1×+8.4×

Where this comes from

Reported directly by Theravance Biopharma in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOperatingLeaseLiability.

The official record: Theravance Biopharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Theravance Biopharma's operating lease liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Theravance Biopharma's operating lease liabilities?: Theravance Biopharma (TBPH) reported operating lease liabilities of -$2.2M in Q1 2026.
How has Theravance Biopharma's operating lease liabilities changed year-over-year?: Theravance Biopharma's operating lease liabilities decreased by 32.2% year-over-year, from -$1.66M to -$2.2M.
What is the long-term trend for Theravance Biopharma's operating lease liabilities?: Over 3 years (2021 to 2025), Theravance Biopharma's operating lease liabilities has grown at a 27.1% compound annual growth rate (CAGR), from -$3.47M to -$7.12M.